论文部分内容阅读
骨髓移植后继发恶性肿瘤临床罕见,但不可避免致死。作者报告1例再生障碍性贫血患者骨髓移植后继发急粒白并作了第2次骨髓移植。患者,女性,42岁,因患再障(Hb10.3g/dl,白细胞2.0×10~9,血小板53×10~9/L)服用康力龙治疗5个月以后,接受了HLA相同的其妹的同种异体骨髓移植,移植前只用了4天环磷酰胺,用量为50mg/kg/d,移植后尽管采用了环孢霉素A预防,但在移植后的第11天产生了Ⅱ-Ⅲ级皮肤和肠的移植物抗宿主病(GVHD),通过甲基强的松龙治疗以后不仅没有再发生急性或慢性GVHD,而且血细胞计数缓慢上升。患
Secondary malignancy after bone marrow transplantation is clinically rare, but inevitably lethal. The authors reported 1 case of aplastic anemia secondary to leukoplakia after bone marrow transplantation and received a second bone marrow transplant. Patient, female, 42 years old, suffered from aplastic anemia (Hb10.3g / dl, white blood cells 2.0 × 10 ~ 9, platelets 53 × 10 ~ 9 / L) Allogeneic bone marrow transplantation, only four days prior to transplantation cyclophosphamide, the dose of 50mg / kg / d, despite the use of cyclosporine A after transplantation prevention, but on the 11th day after transplantation produced Ⅱ-Ⅲ Stage graft versus host disease (GVHD) of the skin and gut, not only did no acute or chronic GVHD recurrence after methylprednisolone treatment, and the blood count increased slowly. Suffering